Evidence map›Paper›PMID 38257761›Full record

ArticleViruses2023

Development and Clinical Performance of InteliSwab

Mark J Fischl, Janean Young, Keith Kardos, Michele Roehler, Tiffany Miller, Melinda Wooten, Natalie Holmes, Nicole Gula, Mia Baglivo, Justin Steen and 14 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 7 institutions in 1 country.

Mark J FischlOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Janean YoungOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Keith KardosOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Michele RoehlerOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Tiffany MillerOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Melinda WootenOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Natalie HolmesOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Nicole GulaOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Mia BaglivoOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Justin SteenOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Nori ZelenzOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Antony George JoyeeOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Vincent MunsterLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Hamilton, MT 59840, USA.ORCID 0000-0002-2288-3196
Zack WeishampelLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Hamilton, MT 59840, USA.
Claude Kwe YindaLaboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, Hamilton, MT 59840, USA.
Kevin G RouseThe Children's Clinic, Jonesboro, AR 72401, USA.
Cathy GvozdenGvozden Pediatrics, Millersville, MD 21108, USA.
David WeverCahaba Research Inc., Pelham, AL 35124, USA.
Giralt YanezSouth Florida Research Organization, Medley, FL 33166, USA.
Marc AndersonTanner Clinic, Layton, UT 84041, USA.
Song YuCahaba Research Inc., MedHelp Urgent Care, Birmingham, AL 32535, USA.
Brian BearieUrgent Care of Colton, Benchmark Research Group, Colton, CA 92324, USA.
Stephen YoungTriCore Reference Laboratories, Albuquerque, NM 87102, USA.
Jody D BerryOraSure Technologies, Inc., 220 East First St., Bethlehem, PA 18015, USA.
Orasure Technologies (United States) · USNational Institute of Allergy and Infectious Diseases · USApplied Research Associates (United States) · USBenchmark Research (United States) · USMillersville University · USNemours Children’s Clinic · USTanner Research (United States) · US

Funding

Biomedical Advanced Research and Development Authority EUA; 75A50120C00061 and 510(k); 75A50121C00078
6 · The paper itself

Abstract

BACKGROUND AND

objectivesTimely detection of SARS-CoV-2 infection with subsequent contact tracing and rapid isolation are considered critical to containing the pandemic, which continues with the emergence of new variants. Hence, there is an ongoing need for reliable point-of-care antigen rapid diagnostic tests (Ag-RDT). This report describes the development, evaluation, and analytical sensitivity of the diagnostic performance of the InteliSwab

resultsThe overall positivity rate by RT-PCR was 37% for the 165 symptomatic subjects. Based on RT-PCR results as the reference standard, InteliSwab

conclusionsDue to the surge of infections caused by different variants from time to time, there is a critical need to evaluate the sensitivity of rapid antigen-detecting tests for new variants. The study findings showed the robust diagnostic performance of InteliSwab

Indexed as

COVID-19SARS-CoV-2Biological AssayBlotting, WesternCOVID-19 TestingHumansCOVID-19diagnosisOmicronrapid antigen testSARS-CoV-2variants of concern

Identifiers

PMID38257761
PMCPMC10821026
OpenAlexW4390412458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.